Morocco’s Cooper Pharma to build antibiotic manufacturing plant in Rwanda

Spotlight

Cooper Pharma, a Moroccan pharmaceutical maker, has inked a deal to build an antibiotic manufacturing facility in Rwanda.

The facility would be the first of its kind in the country, a state official told allAfrica. It is the second such plant construction deal by Cooper, which previously said it signed a deal in Abidjan, Ivory Coast.

The plant in Rwanda is slotted to be built on a nearly 33,000 square-foot plot of land in the Kigalir Special Economic Zone. The facility is expected to open in 2019 and will produce beta-lactam antibiotics, which are among the most commonly prescribed drugs, including Penicillins.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

The deal, which was designed to help meet local pharmaceutical needs, was announced during a three-day state visit by a Moroccan delegation led by King Mohamed VI.

"The market entry of Cooper Pharma… is in line with the long held wish by the government to have a pharmaceutical plant in Rwanda,” Serge Kamuhinda, the COO of the Rwanda Development Board, told allAfrica. “This will reduce our trade deficit and boost exports.”

Read more on

Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

Pfizer is pushing back on a Thursday report claiming it suddenly revised its COVID-19 vaccine targets for 2020, saying it announced that last month.